(CK) activity of twice the normal level or more. The infarct sites were classified into anterior, inferior, non Q wave and Circ J 2005; 69: 420 -426 
reatment for acute myocardial infarction (AMI) has markedly improved during the past 20-30 years, and there has been a corresponding decline in hospital mortality. Joint investigations on ischemic heart disease carried out in Minneapolis and St. Paul, Minnesota report every 5 years on the incidence of AMI, the percentage of patients who received coronary angiography, the use of drugs, the percentage of patients receiving coronary artery bypass grafting (CABG), plain old balloon angioplasty (POBA) or stent therapy, and the mortality rate (Minnesota Heart Survey). 1 According to these investigations, between 1985 and 1995 the percentage of patients administered aspirin increased from 26% to 92% in males, and the percentages of patients who received coronary angiography, emergency angioplasty and CABG increased respectively from 22% to 59%, 2% to 18% and 5% to 10%, while the age-adjusted 28-day mortality rate declined from 13% to 7%. The effects of early and late medical care would seem to have made the greatest contribution to the decline in mortality rates during this period. In Israel, moreover, when treatments for AMI in the coronary care unit (CCU) were compared for the years 1981-1983 (prereperfusion era) and 1992-1994 (reperfusion era), it was found that during the reperfusion era thrombolysis was performed in 45% of patients, percutaneous transluminal coronary angioplasty in 11% and CABG in 4%, and the age-adjusted 30-day mortality in males declined from 17.0% to 9.5% in the reperfused group. 2 According to these investigators, the implementation of new post-AMI therapeutic modalities in daily practice, which had been proven to be effective in clinical trials, probably played a major role in this favorable outcome. The therapeutic outcome of AMI has generally improved with the introduction of new diagnostic modalities and improvements in medication and interventional therapy. In that regard, it is important to monitor changes in the therapeutic outcomes of AMI patients and to confirm that the treatments are producing the expected effects. In the present study, therefore, changes in the treatment of AMI and the related effects on mortality were investigated to evaluate whether the expected results have been obtained with those treatments and whether there are aspects of treatment that need improvement.
Methods
The subjects of this study were patients admitted to our department with AMI within 24 h after onset between 1975 and 2001. The 27 years of the study period were divided into 5 subperiods: 1975 through to April 1982, when the CCU was opened at our hospital; May 1982 through to 1987; 1988 through to 1992; 1993 through to 1997; and 1998 through to 2001. The diagnosis of acute myocardial infarction was based on the characteristic chest pain lasting at least 20 min and accompanied by electrocardiographic signs of ≥0.1 mV of ST-segment elevation in 2 or more limb leads or ≥0.2 mV in 2 or more contiguous precordial leads combined with increases in serum creatine kinaseBackground Many patients with acute myocardial infarction will still die after admission. Recent trends in hospital mortality were analyzed to identify aspects that need improvement. This decrease was particularly marked among those admitted within 6 h of the onset of infarction. Death due to cardiac rupture decreased significantly with time (p<0.001). In contrast, the non-cardiac death rate, amounting to 2.2% on average, did not decline. Conclusions Cardiac deaths due to acute myocardial infarction have decreased markedly of late. However, patients must be admitted within 6 h of the onset of infarction to benefit from this improvement. More effort should be made to improve the general care of patients in order to reduce the incidence of non-cardiac death. T others according to appearance of abnormal Q waves on ECG after the onset of infarction. Q wave was defined as abnormal when its duration (from the point where it leaves the baseline) was 0.04 s or longer and its magnitude was greater than 25% of the height of the succeeding R wave. Infarct site was defined anterior if abnormal Q wave appeared in V2-6 or I, aVL, inferior if appeared in II, III and aVF. Lateral infarction (abnormal Q in I, aVL and V6) was included in anterior infarction category and posterior infarction (high R wave in V1,2) was included as inferior infarction. If there were no abnormal Q waves it was defined as non Q wave infarction. The 'others' infarct site cateory indicates those that were difficult to classify according to the above definition. Serial blood samples were taken every 3 h to identify CK elevation and peak CK. Spontaneous angina accompanied by ST segment elevation was regarded as vasospastic angina. In patients who exhibited clinical signs and symptoms of vasospastic angina, but had no ECG record, acetylcholine or ergonovine coronary angiography were undertaken, and a diagnosis of vasospastic angina was made when chest pain, changes in ECG and coronary vasospasms were present. Coronary angiography was performed immediately after admission in those for whom it was indicated. In some patients, coronary angiography was performed the next day (after 24 h), occasionally with percutaneous coronary intervention. 3 Coro- nary angiography was repeated approximately 1 month after the onset of infarction in many cases. The application of this follow-up angiography was determined by the attending physician. There were no departmental rules regarding the need to perform follow-up angiography or not. Patients who underwent coronary angiography at any point during their hospitalization were classified as having undergone angiography. The infarct-related artery (IRA) was determined on the basis of findings on coronary angiography, ECG and echocardiography during the acute phase.
Methods and Results
If the IRA could not be identified, it was classified as 'other'. Mortality during hospitalization of approximately 1 month was studied. Cardiac death included: death due to cardiogenic shock; free wall rupture; ventricular septal rupture (VSR); recurrent myocardial infarction (reMI); congestive heart failure; or fatal arrhythmias, operative death, sudden death and other cardiac death. Deaths due to causes other than those listed above were defined as noncardiac deaths, and the sum of cardiac and non-cardiac deaths was regarded as the total mortality.
All procedures are conducted under the approval of our institutional guidelines for clinical studies. Informed consent was obtained for all clinical studies when necessary.
Values are expressed as means ± standard deviations. Differences between the means of 2 groups were evaluated using non-paired t-tests; values of p<0.05 were considered significant. Changes in the values among subperiods were evaluated using the trend test. For categorical data, the Mantel -Haenszel chi-squared test was used as the measure of trend. For continuous data, one-way analysis of variance was used to test the null hypothesis that multiple popula- tion means were all equal. Multivariate logistic analysis was performed to find independent factors on 10 factors as shown in Table 1 to predict survival after admission and discharge alive approximately 1 month after admission. Calculations on each IRA were done against the right coronary artery. All statistical analyses were carried out using a commercially available statistical package (SPSS 12.0 [2003], SPSS Japan Inc, Tokyo, Japan). Table 2 shows the numbers and characteristics of patients admitted with AMI during the 27-year period covered in this study. A nearly constant number of patients were admitted annually during the CCU era (mean: 46.2 patients/year) totaling 1,247 patients in all.
Results

Changes in the Patients' Characteristics
No significant changes were observed in the gender, age, time from the onset of myocardial infarction (MI) to admission to the CCU, infarct site, severity of MI according to the Killip and Forrester classifications or peak CK. MI was complicated by vasospastic angina in 2.7% of all patients. The percentage of patients who underwent coronary angiography was 43.9% before the establishment of the CCU, but this had increased to 89.8% by the 1998-2001 subperiod (p<0.01). The percentage of patients whose IRA could not be identified declined, and those with left main trunk infarction increased. Thrombolytic therapy was performed in 60.5% of patients between 1993 and 1997, but this percentage declined to 30.9% thereafter. In contrast, the percentage of patients receiving POBA gradually increased (p<0.01) over the study period, as did the percentage of those receiving stents, which reached 45.5% after 1998 (p<0.01). The percentage of patients who received CABG during hospitalization also increased gradually, reaching 15.9% after 1998 (p<0.01).
Patency of the IRA
Coronary angiography administered upon admission showed 100% occlusion of the IRA in 60.1% of patients (Table 3) . Those showing 50% stenosis or less accounted for only 2.3% of patients. Among those who discharged alive, 56.6% had discharge coronary angiography approximately 1 month after onset. Table 3 shows the patency of IRA on these patients. Patients who were discharged still having 100% occlusion gradually declined over the study period, reaching 2.1% after 1998 (p<0.01), while those discharged with 50% stenosis or less gradually increased to 82.5% during the same period (p<0.01).
Hospital Mortality
One hundred and eighty-two deaths (14.6%) occurred during the study period (Table 4) . Of those, 154 (12.3%) were cardiac deaths and 28 (2.2%) were non-cardiac deaths. There were 21 (13.6%) deaths among 154 cardiac deaths on the 1st hospital day, 15 (9.7%) on the 2nd hospital day, 10 (6.5%) on the 3rd hospital day, 19 (12.3%) on the 4-7th hospital days, 18 (11.7%) on the 8-14th hospital days (2nd week), 5 (3.2%) in the 3rd week, 6 (3.9%) in the 4th week, and 23 (14.9%) thereafter. The average time from the onset of MI to cardiac death was 25.1±82.3 days. The causes of non-cardiac death were infections in 12 patients (6.6% of 182 deaths), cerebrovascular disorders in 5 (2.7%), renal failure in 4 (2.2%), multiple organ failure in 4 (2.2%), and bleeding in 3 (1.6%). Non-cardiac deaths occurred on an average of 71.4±138.5 days after the onset of MI, with 7 (25.0% of 28 non-cardiac deaths) occurring during the 1st week, 2 (7.1%) during the 2nd week, 0 during the 3rd week, 2 (7.1%) during the 4th week and 17 (60.7%) thereafter.
Changes in the Cardiac Death and Total Mortality Rrates
The rate of cardiac death decreased significantly from 17.1% to 7.7% over the study period (p<0.01; Fig 2) . The total mortality rate also declined significantly from 19.5% to 10.2% (p<0.05), but the total mortality and cardiac death rates declined in parallel, and there was no decrease in the rate of non-cardiac death (2.2%; Table 4 ).
Changes in the Causes of Cardiac Death
Among the cardiac deaths, death due to cardiac rupture (including 3 patients with VSR) decreased significantly from 9.8% to 2.8% (p<0.001) over the study period. Among 743 patients with reperfusion therapy there were 21 cases (2.8%) with cardiac rupture, while it was 26 cases (5.2%) among 497 patients without reperfusion therapy. If we include the ruptured case and those who survived, the frequency of cardiac rupture decreased progressively (p<0.001) over the course of the 5 subperiods, from 9.8% (4/41) to 3.7% (11/295), to 4.6% (16/351, including 2 cases of VSRs), to 1.9% (6/314 including 2 cases of VSRs), to 4.1% (10/246 including 1 VSR). The survival rate after cardiac rupture was 0% (0/4), 0% (0/11), 37.5% (6/16), 16.7% (1/6) and 30.0% (3/10) during the respective subperiods. Notably, hospital mortality due to cardiac rupture was reduced after 1993 and the survival rate after cardiac rupture increased after 1988.
Fatal reMI was observed in 1.6-4.3% of the patients before 1997 and was one of the major causes of cardiac death, along with cardiogenic shock, cardiac rupture and congestive heart failure, but only 1 patient (0.4%) died of fatal reMI after 1998 (Table 4) . After 1996, when stent therapy was introduced, 258 of 394 patients were treated without the use a stent. Of these, reMI occurred in 13 (5%); it was fatal in 3 (1.2%) and non-fatal in 10 (3.9%). Of the 136 patients treated with a stent, there were no fatal reMIs and only 3 (2.2%) non-fatal reMIs.
Changes in the Cardiac Death Rate With Respect to the Time From the Onset of MI to Admission
Annual changes in the cardiac mortality rate were reviewed for patients admitted immediately after the onset of their MI and those admitted late after onset. Between 1975 and April, 1982, the cardiac mortality was 25.0% among those admitted within 3 h after onset and 50% among those admitted within 4-6 h after onset; between May 1982 and 1987, the rates were 22.4% and 32.6%, respectively. The rates declined markedly to 3.2% and 6.1%, respectively, by the 1998-2001 subperiod (p<0.01). In contrast, the cardiac death rate was 29.6% among those admitted within 7-12 h after onset and 20.0% among those admitted within 13-24 h after onset between 1975 and April 1982; 25.6% and 19.0%, respectively, between May 1982 and 1987; and 23.3% and 9.8%, respectively, between 1998 and 2001. There was also no clear reduction the rate of non-cardiac death.
Changes in the Total Mortality Rate With Respect to the Severity of AMI
The incidence of Forrester I was 60.1% (Table 2 ) with a total mortality rate of 5.6% over the entire study period. The incidence of Forrester II was 11.7% with a mortality rate of 13.1%, Forrester III was 18.0% with a mortality rate of 14.5% and Forrester IV was 10.2% with a mortality rate of 44.2%. Although total mortality in all Forrester subsets declined with time, it remained as high as 36.8% in Forrester IV, most recently (Fig 3) . Thus, the mortality rate declined significantly, regardless of the severity of AMI (trends: p<0.01 for Forrester I, p<0.05, for Forrester II, p<0.01 for Forrester III, p<0.05 for Forrester IV).
Changes in the Mortality Rate With Respect to Treatment
The mortality rate was summarized with respect to treatment for patients after 1987, when reperfusion therapy began to be performed frequently. Among the 378 patients who received conservative treatment alone, there were 103 deaths (27.2%); among the 393 who received thrombolytic therapy alone, there were 58 deaths (14.8%, p<0.01); among the 51 who received POBA and no thrombolysis, there were 7 deaths (13.7%, p<0.01); and among the 74 who received stenting, with or without POBA and no thrombolysis, there were 4 (5.4%, p<0.01) deaths.
Multivariate Logistic Analysis to Predict Survival After Admission
Stent therapy on admission was the only independent factor to improve survival after admission. In contrast, left main trunk disease had the highest odds ratio (OR) against hospital survival, although this was statistically not signifi- cant. Multivessel disease and ageing were significant factors against hospital survival (Table 1) .
Discussion
The present study summarizes the changes in the clinical features of AMI, coronary patency, treatments and mortality rates for AMI that occurred during the 27-year period from 1975 to 2001 in our CCU. The percentage of patients who were discharged with 100% occlusion of the IRA declined to 2.1%; most recently, 82.5% were discharged with 50% stenosis or less. This decline has been associated with progressive declines in hospital mortality due to cardiac death, which was only 7.7% after 1998. According to the present study, coronary stenting on admission is the most effective therapy to improve the prognosis. In contrast, the rate of non-cardiac death did not decline and remained at 2.2%.
Improved Patency of the IRA
As mentioned, the percentage of patients discharged with complete occlusion of the IRA decreased markedly after 1998 to 2.1%; 82.5% of the patients were discharged with a residual stenosis of 50% or less. This satisfactory patency of the IRA is almost certainly the result of increases in the use of stent therapy, thrombolytic therapy and POBA, and patency of the IRA leads to reduced hospital mortality and improved long-term prognosis. [4] [5] [6] The marked improvement in the hospital mortality among patients admitted within 6 h of the onset of MI supports this concept. In addition, the multivariate analysis by Dönges et al showed that the use of thrombolytic therapy during the acute phase, primary angioplasty and the use of -blockers are all factors that prevent the occurrence of reMI. 7 Thus, the decrease in the hospital mortality observed in that study is likely to reflect the fact that only mild residual stenosis remained after reperfusion therapy. Our facility previously reported that the long-term prognosis of AMI improved greatly during the period between 1986 and 1999, and that the incidence of cardiac events decreased from 6.0% (44.9 cases/1,000 patient ·years) to 1.6% (22.5 cases/1,000 patient ·years). 8 The improved post-AMI revascularization strategies based on thrombolysis, POBA and stenting would appear to be a major reason for the improved hospital prognosis and prognosis after discharge. The beneficial effects of reperfusion therapy on mortality were reported in the recent TETAMI (Treatment with Enoxaparin and Tirofiban in Acute Myocardial Infarction) trial, and a similar decrease in hospital mortality was reported by the Miyagi Study Group, which studied changes in the treatment and mortality rates for AMI between 1992 and 2000. 9, 10 The decrease in the number of cardiac deaths reported in that study can be attributed to the implementation of new therapeutic modalities.
Decreases in Cardiac Rupture
While the hospital mortality declined in general, deaths due to free wall rupture decreased to a significantly greater degree. It is particularly noteworthy that a considerable percentage of patients survived free wall rupture. According to the United States National Registry, in 1996, death due to cardiac rupture was responsible for 12.1% of hospital deaths among 122,243 registered patients who received thrombolytic therapy, but was only 6.1% of those among 228,517 not treated with thrombolytics, suggesting cardiac rupture is a major complication with this therapy. 11 However, according to the metaanalysis by Honan et al, who carefully evaluated the incidence of cardiac rupture with respect to the time from the onset of MI to the beginning of thrombolytic therapy, the incidence of cardiac rupture was significantly reduced when thrombolytic therapy was administered within 7 h after onset (OR 0.4, 95% confidence intervals (CI) 0.17-0.93); the increased and decreased incidences cancelled each other out when the therapy was administered 11 h after onset (OR 0.93, 95%CI 0.53-1.60); and the incidence of cardiac rupture was significantly increased when therapy was administered 17 h after onset (OR 3.21, 95%CI 1.10-10.1). 12 Because coronary thrombolysis is mostly performed within 6 h after onset in Japan, this treatment would contribute to the reduction of the incidence of cardiac rupture.
According to a recent analysis by Ikeda et al, cardiac rupture occurred in 3.5% of the 1,296 AMI patients treated between 1992 and 2002, but the incidence was only 0.6% among patients successfully treated with reperfusion therapy. 13 In addition, 24 (53.3%) of the 45 patients with cardiac rupture (including 20 patients with VSR) were discharged alive. Since most of our 37 patients with cardiac rupture had free wall rupture, with only 5 having VSR, our results may not be directly comparable to those of Ikeda et al. 13 Nevertheless, it seems plausible that reperfusion therapy reduces the incidence of cardiac rupture and that its early diagnosis using echocardiography and immediate treatment thereafter are effective for preventing death.
Decreases in Recurrent MI
Before the era of stent therapy, which began in 1997, cardiogenic shock, cardiac rupture, reinfarction and heart failure were major causes of death among AMI patients. The analysis by Ishikawa et al of data for 1985 and 1999 showed that in those years fatal reMI accounted for 1.1% and 0.7% of cardiac deaths, respectively, constituting one of the major causes of cardiac death in those patients. 8 A National Survey in the United States also reported that in 1994 0.7% of AMI patients died due to reMI. 11 However, the present study shows that this percentage declined to 0.4% by 1998-2001; moreover, after the introduction of stent therapy, no deaths due to reMI were observed in the group receiving stents, whereas 1.2% of patients treated without stenting died as a result of reMI, although this difference was statistically not significant. Apparently, stent therapy plays a critical role in the prevention of reMI.
No Decrease in Non-Cardiac Deaths
It is extremely regrettable that there has been no reduction in the rate of non-cardiac deaths since 1975. All noncardiac deaths were caused by complications that occurred during the course of treatment for AMI, highlighting the importance of general care, in addition to cardiac management, of these patients. Also, we need to introduce new strategies to reduce mortality in the complicated cases with AMI, such as Forrester IV, because the level of fatalities remains high.
Study Limitation
Although the present study highlights recent declines in hospital mortality among AMI patients, the efficacy of the therapies, including reperfusion therapy, cannot be judged without a large randomized clinical trial. In addition, the present result, which is based on a single institution, cannot be extrapolated to the national trends in Japan.
In conclusion, cardiac death after AMI has been reduced considerably over these 27 years in our department. The reduction in deaths due to cardiac rupture and recurrent MI are especially prominent, possibly due to the implementation of new therapeutic strategies such as stenting. However, it is surprising that non-cardiac death have not been reduced during the study period, which necessitates the improvement of general care of the AMI patients.
